Tom Waddell

6PUBLICATIONS
50CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial.

|Aug 01, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Brian I Rini, Elizabeth R Plimack, Viktor Stus

|May 07, 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study.

Anderley Gordon, David Cunningham, Zayn Rajan

|May 02, 2025
MANIFEST: Multiomic Platform for Cancer Immunotherapy.

Kok Haw Jonathan Lim, Zayd Tippu, Pippa G Corrie

|Oct 09, 2024
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Tom Waddell, Manon Pillai, Kate Armitage

|Sep 10, 2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Nigel Fleeman, Rachel Houten, Sarah Nevitt

Pageof 1

Frequent Collaborators

2 joint publications

Ian Chau

2 joint publications

David Cunningham

2 joint publications

Anderley Gordon

1 joint publications

Russell Petty